Pipeline Overview

Program
Target
Indications
Discovery
Pre-clinical development
Early development
Late development
Rights
Program: Cemsidomide
Target: IKZF1/3
Multiple Myeloma & Non-Hodgkin’s Lymphoma
Indications Multiple Myeloma & Non-Hodgkin’s Lymphoma
MM
Early development
Indications Multiple Myeloma & Non-Hodgkin’s Lymphoma
NHL
Early development
Right 1
Program: CFT8919¹
Target: EGFR L858R
Non-Small Cell Lung Cancer
Indications Non-Small Cell Lung Cancer
Early development
Right 1 Right 2
Program: CFT1946²
Target: BRAF V600 Mutant
V600 Mutant Cancers
Indications V600 Mutant Cancers
CRC
Early development
Indications V600 Mutant Cancers
Melanoma
Early development
Indications V600 Mutant Cancers
Other BRAF V600 Mutant Cancers
Early development
Right 1
Program: Discovery Stage Programs³
Oncology & Non-Oncology Indications
Indications Oncology & Non-Oncology Indications
Discovery
Right 1

1 License and collaboration agreement with Betta Pharmaceuticals for development and commercialization in Greater China

2 In May 2025, C4T announced CFT1946 will not advance beyond Phase 1 and that the company will seek partnership for the BRAF program

3 C4T is pursuing 5 targets in the following pathways: IL-23/IL-17; Type 1 IFN; MAPK, P13K/AKT, NF-kB

Learn more about our partnerships